Skip to content
OpenCapital
Get started

Amgen AMGN Otezla — Total revenues

Other product segments

Repatha
$3.02B—
Other products
$1.53B+3.6%
Prolia
$727M-33.8%
EVENITY
$562M+27.1%
TEPEZZA
$490M+28.6%
BLINCYTO
$415M+12.2%
Nplate
$412M+31.6%
XGEVA
$411M-27.4%
TEZSPIRE
$343M+20.4%
KYPROLIS
$330M+1.9%
ENBREL
$320M-37.3%
Aranesp
$311M-8.5%
Vectibix
$287M+7.5%
UPLIZNA
$262M+188%
IMDELLTRA/IMDYLLTRA
$258M+219%
KRYSTEXXA
$255M+8.1%

Similar metrics at other companies

Supernus Pharmaceuticals logo
SUPNOxtellar XR — Total revenues
$7.42M-27.2%
United Therapeutics logo
UTHROrenitram — Total revenues
$135.6M+12.3%
Incyte logo
INCYOPZELURA — Total revenues
$449.74M+173%
Organon logo
OGNOntruzant — Revenue
$5M-72.2%
PBH
PBHOther OTC — Total revenues
$5.35M+39.2%
Ligand Pharmaceuticals logo
LGNDOhtuvayre — Total revenues and income
$2.99M+112%

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$212.16B+30.0%
Enterprise value$268.92B+22.9%
P/E27.2×+2.5×
P/S5.7×+1.0×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's otezla — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's otezla — total revenues?
Amgen (AMGN) reported otezla — total revenues of $431M in Q1 2026.
How has Amgen's otezla — total revenues changed year-over-year?
Amgen's otezla — total revenues decreased by 1.4% year-over-year, from $437M to $431M.
What is the long-term trend for Amgen's otezla — total revenues?
Over 4 years (2021 to 2025), Amgen's otezla — total revenues has grown at a 0.2% compound annual growth rate (CAGR), from $2.25B to $2.27B.
What does otezla — total revenues mean?
This represents the total gross sales generated by a specific pharmaceutical product line within the company's portfolio. It reflects the market demand, pricing power, and commercial success of the therapeutic agent in its indicated disease areas. Monitoring this helps assess the product's lifecycle stage and its contribution to the overall corporate revenue stream.